Name: Recombinant Anti-CD33 x Anti-DENV Bispecific Antibody (sdAb-Fc-sdAb)
SKU: HCAB-035
Rating: 5 (1 reviews)

Recombinant Anti-CD33 x Anti-DENV Bispecific Antibody (sdAb-Fc-sdAb, Tetravalent Heavy Chain-only Antibody, Tetravalent HCAb) is symmetric protein with two pairs of single domain antibodies (sdAb), from anti-CD33 and anti-DENV antibodies. The VH and VL domains form an inter-chain pairing. The diabody with different specificities is fused to the Fc fragment, which results in 2+2 antigen-binding valency and exerts Fc-mediated functions or just extends the half-life. This BsAb is designed for the research of antibody-dependent enhancement (ADE) and dengue virus infection.

Datasheet INQUIRY

Specifications

Targets

CD33 & DENV

Type

sdAb-Fc-sdAb

Species Reactivity

Human

Application

FuncS

Related Disease

Dengue virus infection

Host Animal 1

llama

Host Animal 2

llama

Targets

Target 1

CD33

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Target 2

DENV

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD33 x Anti-DENV Bispecific Antibody (sdAb-Fc-sdAb) (HCAB-035). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD33 x Anti-DENV Bispecific Antibody (sdAb-Fc-sdAb) (CAT#: HCAB-035)

Specifications

Targets

Customer Reviews and Q&As